_2020091018165303jzv.jpg "Decoding The World Of ETF")
-
My Account
Partnered by:
Associate Partners:
My Account
Partnered by:
Associate Partners:
Partnered by:
Associate Partners:
BSE Live
Jan 25, 16:00Prev. Close
5033.80
Open Price
5059.65
Bid Price (Qty.)
5075.90 (253)
Offer Price (Qty.)
5085.00 (3)
NSE Live
Jan 25, 16:05Prev. Close
5036.90
Open Price
5042.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5082.40 (416)
| Half Yearly Results of Dr Reddys Laboratories (in Rs. Cr.) | Sep '20 | Mar '20 | Sep '19 | Mar '19 | Sep '18 | |
| Net Sales/Income from operations | 6,570.40 | 5,881.90 | 5,954.70 | 5,312.10 | 5,154.60 | |
| Other Operating Income | 19.80 | 13.80 | -- | 64.80 | 94.00 | |
| Total Income From Operations | 6,590.20 | 5,895.70 | 5,954.70 | 5,376.90 | 5,248.60 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,604.70 | 1,327.30 | 1,229.20 | 1,069.40 | 1,033.80 | |
| Purchase of Traded Goods | 604.60 | 572.20 | 545.00 | 494.00 | 374.60 | |
| Increase/Decrease in Stocks | -328.70 | -32.90 | -67.00 | 81.20 | -15.20 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 1,153.00 | 1,027.80 | 1,002.40 | 961.90 | 970.00 | |
| Depreciation | 411.90 | 388.10 | 401.10 | 397.70 | 382.90 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | 1,799.30 | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | -- | 1,724.80 | 1,653.60 | 1,646.90 | 1,719.20 | |
| P/L Before Other | 1,345.40 | 888.40 | 1,190.40 | 725.80 | 783.30 | |
| Other Income | 659.30 | 196.70 | 548.10 | 165.50 | 82.90 | |
| P/L Before Int. | 2,004.70 | 1,085.10 | 1,738.50 | 891.30 | 866.20 | |
| Interest | 23.30 | 23.50 | 24.30 | 24.50 | 32.30 | |
| P/L Before Exceptional Items & Tax | 1,981.40 | 1,061.60 | 1,714.20 | 866.80 | 833.90 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 1,981.40 | 1,061.60 | 1,714.20 | 866.80 | 833.90 | |
| Tax | 550.20 | 37.10 | -199.00 | 264.60 | 158.80 | |
| P/L After Tax from Ordinary Activities | 1,431.20 | 1,024.50 | 1,913.20 | 602.20 | 675.10 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 1,431.20 | 1,024.50 | 1,913.20 | 602.20 | 675.10 | |
| Equity Share Capital | 83.10 | 83.10 | 83.10 | 83.00 | 83.00 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 86.31 | 61.64 | 115.42 | -- | 40.67 | |
| Diluted EPS | 86.08 | -- | 115.21 | -- | 40.62 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 86.31 | 61.64 | 115.42 | -- | 40.67 | |
| Diluted EPS. | 86.08 | -- | 115.21 | -- | 40.62 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
29.10.2020
Dr Reddys Labs Consolidated September 2020 Net Sales at Rs 4,910.90 crore, up 2.04% Y-o-Y
29.10.2020
Dr Reddys Labs Standalone September 2020 Net Sales at Rs 3,345.80 crore, down 2.91% Y-o-Y
28.10.2020
Dr Reddy's Labs Q2 profit falls 30% to Rs 762 crore, global generics business up 21%
29.08.2020
22.01.2021
18.01.2021
Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher
29.07.2020
Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%
14.10.2019
